DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
INDEGENE

INDEGENE Latest Share Price (INDGN)

₹609.75
3.60−0.59%
Overall Score57/100
Day range600
₹609.75
618
52-week414
₹609.75
638
Above low+47.3%
Below high4.4%
Range position87%
Open611.00
Prev Close613.35
Bid609.72100
Ask609.78100

TODAY IN ONE LINE

INDGN slipped 0.6% on average volume, lagging Nifty's 2.0% move.

With a market cap of ₹14,697.77 Cr., it trades at a P/E of 35.71. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume226.3K−52%vs 20D avg
Price Band20
Lower Band470.5
Upper Band705.7
Tick Size0.05
Daily Volatility1.84%
Annualised Vol35.15%
Market Cap₹14,697.77 Cr.
Promoter—
Face Value₹2
Fwd P/E20.46
PEG2.13
EV/EBITDA11.55
P/S3.58
ROA7.75%
Beta0.84
Div Payout11.97%
THE STOCK SCORE
Overall Score57/100
Updated 06 Nov

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

INDEGENE flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 2 red flags

Green Flags

  • ●Healthy Operating MarginsOPM is structurally strong at 23.8%
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●FII AccumulationFII holding increased by 2.49% QoQ
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • ●Earnings DeclineEPS (TTM) has contracted by 32.3% YoY
  • ●Rising Receivables vs SalesReceivables grew 18.4% outpacing sales growth of 9.6%

Latest INDEGENE News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

INDEGENE valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for INDEGENE, framed against the sector median so the premium or discount is obvious at a glance.

INDEGENE trades at a P/E of 35.71× and P/B of 4.37×, against the Healthcare sector median P/E of 48.41×.

Key MetricsMarket + reported · 06 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹14,697.77 Cr.
P/E Ratio
35.71
P/B Ratio
4.37
EPS
₹4.66
Profitability

Profitability

ROE
10.19%
ROCE
10.81%
Net Margin
12.03%
Op Margin
23.77%
Growth

Growth

EPS YoY
-32.3%
Revenue YoY
32.8%
Qtr Sales
5.57%
Qtr Profit
-3.36%
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹130.25
Div Yield
0.37%
Promoter Holding
—
Technicals

INDEGENE technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDEGENE — derived from the latest tape, not yesterday's close.

INDEGENE last traded at ₹609.75 with an intraday range of ₹600–₹618 — latest indicator, pivot and CPR signals below.

Last updated: 8 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹609.75
LevelPrice (₹)Distance% Δ
R4654.50+44.75+7.34%
R3636.50+26.75+4.39%
R2627.25+17.50+2.87%
R1618.50+8.75+1.44%
PIVOT609.25-0.50-0.08%
CURRENT609.75——
S1600.50-9.25-1.52%
S2591.25-18.50-3.03%
S3582.50-27.25-4.47%
S4564.50-45.25-7.42%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 609.00P: 609.25TC: 609.50
R1
R2
R3
R4
indicator
LTP: 609.75
PDH: 636.20
PDL: 611.55
● Market Sentiment

INDGN is trading Above CPR, indicating Bullishness

● CPR Width

CPR is Narrower, suggesting likely for trending moves

● Opening Range

Day's range: ₹600–₹616.5

● Price Position

Trading Below opening range, showing Bearishness

Financials

INDEGENE financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for INDEGENE — consolidated or standalone — with margins, YoY growth and key ratios inline.

INDEGENE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹14,697.77 Cr. and reported EPS of ₹4.66.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026Apr 2026
Revenue from Operations3,511
3,511
▲ 0.0%
Sales Growth YoY %Derived23.64%
23.64%
Other Income72
72
▲ 0.0%
Total Income3,583
3,583
▲ 0.0%
2,892
2,892
▲ 0.0%
EBITDA (Operating Profit)Derived619
619
▲ 0.0%
OPM %Derived17.63%
17.63%
125
125
▲ 0.0%
Profit Before Tax (PBT)525
525
▲ 0.0%
124
124
▲ 0.0%
Effective Tax %Derived23.60%
23.60%
Total Profit for Period401
401
▲ 0.0%
Net Profit (Owner's PAT)Derived401
401
▲ 0.0%
Net Profit Margin %Derived11.43%
11.43%
PAT Growth YoY %Derived-1.38%
-1.38%
Earnings Per Share (EPS ₹)16.65
16.65
▲ 0.0%
Diluted Shares Outstanding (Cr)24
24
▲ 0.0%
Other Comprehensive Income (Net of Tax)139
139
▲ 0.0%
Total Expenses (incl. D&A & Interest)3,058
3,058
▲ 0.0%
Material Cost % of RevenueDerived—
—
Employee Cost % of RevenueDerived62.60%
62.60%
Other Cost % of RevenueDerived19.76%
19.76%
Interest Coverage (x)Derived25.52x
25.52x
Sales CAGR · 3Y
+7.3%
Sales CAGR · 5Y
+6.3%
PAT CAGR · 3Y
-0.5%
PAT CAGR · 5Y
+3.6%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

INDEGENE segment analysis : revenue and profit mix.

Disclosed business segments at INDEGENE with their share of revenue and profit, switchable between consolidated and standalone reporting.

INDEGENE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for INDEGENE.

Our AI distills the core fundamental drivers supporting INDEGENE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 46 (~1.0× the sector multiple of 48.4) would leave less room for earnings disappointment.

  • Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.

  • Watch wage inflation and attrition rates — primary threats to operating leverage in IT.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

Shareholding

INDEGENE shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in INDEGENE — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Public71.77%↓9.57%
DII15.82%↑7.08%
FII12.40%↑2.49%

Ownership Distribution

Retail & Public
71.77%
Domestic Institutions
15.82%
Foreign Institutions
12.40%

Category Trends

Foreign Institutions Breakdown
Total Holding: 12.40%
Net Change: +2.49%
Category Total12.40%
Total Holding12.40%
Net Change+2.49%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 6.52%, but category aggregate is 12.40%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Government Pension Fund Global
2.77%
0.20%
+0.20%
Sep 2026
FIDELITY FUNDS - INDIA FOCUS FUND
1.34%
0.16%
-0.16%
Sep 2026
Smallcap World Fund, Inc
1.31%
0.11%
-0.11%
Sep 2026
Mfs International New Discovery Fund
1.10%
1.10%
+1.10%
Sep 2026
Peers

INDEGENE peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDEGENE is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SYNGENE INTERNATIONAL
₹16,812.82 Cr
Best Profit Growth
SYNGENE INTERNATIONAL
457.78 %
Highest Dividend Yield
VIMTA LABS
0.40 %
09 · Chart Patterns

INDEGENE chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for INDEGENE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

INDEGENE delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for INDEGENE over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in INDEGENE stood at 56.1% of traded volume, against a 20-day average of 59.9%.

Avg Delivery (20D)59.9%-3.8 ppt latest vs avg
Highest Delivery78.8%on 23 Oct
Avg Volume (20D)4.73 L20-day run-rate
Conviction Trend↓ Weakening-3.8 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

INDEGENE announcements: results, concalls, ratings, M&A.

Filings INDEGENE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

INDEGENE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 234 documents below.

  1. 31 Oct 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Indegene Limited has informed the Exchange about Copy of Newspaper Publication

  2. 30 Oct 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Indegene Limited has informed the Exchange about Link of Recording

  3. 29 Oct 2026Resignation of Director/KMP/SMPView PDF

    Resignation of Director/KMP/SMP

    Indegene Limited has informed the Exchange about Resignation of Director/KMP/SMP

  4. 29 Oct 2026Investor PresentationView PDF

    Investor Presentation

    Indegene Limited has informed the Exchange about Investor Presentation

  5. 29 Oct 2026Press ReleaseView PDF

    Press Release

    Indegene Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Indegene Delivers Strong Q2 FY27 Performance, H1…

Corporate Actions

INDEGENE dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue INDEGENE has declared, sequenced by announce and record date.

INDEGENE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

INDEGENE insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in INDEGENE as reported to SEBI — buying and selling signals from the people who know the business best.

INDEGENE insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Anita NairInsider19 Mar 2026buy+22.2 K₹99.98 L₹449.76
Anita NairInsider19 Mar 2026buy+22.2 K₹99.98 L₹449.76
Anita NairInsider19 Mar 2026buy+22.2 K₹99.98 L₹449.76
Anita NairInsider19 Mar 2026buy+22.2 K₹99.98 L₹449.76
Anita NairInsider19 Mar 2026buy+22.2 K₹99.98 L₹449.76
Manish GuptaInsider24 Dec 2024buy+17.0 K₹1.02 Cr.₹599.19
Rajesh Bhaskaran NairInsider23 Dec 2024buy+25.0 K₹1.5 Cr.₹598.26
Sanjay Suresh ParikhInsider20 Dec 2024buy+16.5 K₹1 Cr.₹606.52
Rajesh Bhaskaran NairInsider17 Dec 2024buy+1.00 L₹5.96 Cr.₹595.81
About the Company

About INDEGENE: business, sector, key facts.

What INDEGENE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

INDEGENE operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: INDGN, BSE: 544172.

INDGN
Healthcare

INDEGENE

NSE · INDGN·BSE · 544172·www.indegene.com

Indegene Limited is a global digital-first life sciences commercialization company headquartered in Bengaluru, India, with a significant presence in the United States and Europe. The company's core business revolves around providing comprehensive services and technology solutions to biopharmaceutical, emerging biotech, and medical device companies across their entire product lifecycles.

Indegene's operations are structured into three primary segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The Enterprise Medical Solutions segment focuses on providing medical and clinical solutions, supporting the development and regulatory aspects of new products. This likely includes services such as medical affairs, regulatory strategy, and clinical trial support.

The Enterprise Commercial Solutions segment caters to the commercial aspects of bringing products to market. This likely encompasses services such as market research, sales force effectiveness, pricing and market access strategy, and overall commercial strategy development and execution. These services are crucial for maximizing product uptake and return on investment.

The Omnichannel Activation & Others segment likely incorporates a range of solutions aimed at integrating various channels for effective communication and engagement with healthcare professionals and patients. This might include digital marketing, content creation, and multi-channel campaign management to promote products and build brand awareness. The "Others" component likely encompasses additional services that complement the core offerings, potentially including consulting or specialized technology services.

A key aspect of Indegene's business model is its reliance on NEXT technology platforms. These platforms likely represent a suite of proprietary technologies and tools designed to enhance efficiency and effectiveness across its various service offerings. These platforms could include data analytics dashboards, CRM systems tailored for the life sciences industry, or other specialized software.

In summary, Indegene acts as a comprehensive partner for life sciences companies, providing a blend of consulting, technology, and services to navigate the complexities of research, development, and commercialization. Their integrated approach across medical, commercial, and omnichannel activation ensures a holistic support system for clients throughout the entire product lifecycle.

company facts
Employees—
SectorHealthcare
HeadquartersBengaluru, India
Market Cap₹14,697.77 Cr.
Listed OnNSE
leadership29 on record
Abhishek Agarwal
Head of Investor Relations
Dr. Ashish Gupta
Non-Executive Independent Director
Dr. Georgia Papathomas
Non-Executive Independent Director
Dr. Rajesh Nair
Non-Executive Director, President of Indegene, Inc.
Dr. Sanjay Parikh
Executive Vice President, Executive Director
Dr. Sanjay Suresh Parikh Ph.D.
Executive Director & Executive VP
Mr. Anand Kiran Prafula Chandra Nijegal
Executive Vice President of Global Operations
Mr. Anand Nijegal
Executive Vice President - Global Operations
Mr. Gaurav Kapoor
Executive Vice President of Indegene, Inc.
Mr. Jairaj Purandare
Non-Executive Independent Director
Mr. Karthik Kannappan Saravanan
VP of Legal & Group General Counsel
Mr. Krishnamurthy Tenneti
Non-Executive Independent Director
§ ∞ · Plainly Answered

Questions investors ask about INDEGENE (INDGN).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of INDEGENE (INDGN)?

The current share price of INDEGENE (INDGN) is ₹609.75. Today, the stock has declined by ₹3.60 (0.59%), trading in a range of ₹600.00 to ₹618.00. The stock opened at ₹611.00 with a trading volume of 2,26,254 shares.

02Is INDEGENE stock a good investment for long-term?

INDEGENE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,697.77 Cr., P/E ratio of 35.71, ROE of 10.19%, and ROCE of 10.81%. The dividend yield stands at 0.37%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of INDEGENE stock?

The 52-week high price of INDEGENE (INDGN) is ₹638.00, while the 52-week low is ₹414.00. Currently trading at ₹609.75, the stock is 47.28% above its 52-week low and 4.43% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy INDEGENE stock at the current price?

Whether to buy INDEGENE stock at ₹609.75 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.71 and P/B ratio of 4.37. Today's performance shows a loss of 0.59%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of INDEGENE and when is the next dividend?

INDEGENE offers a dividend yield of 0.37%, which means for every ₹100 invested at the current price of ₹609.75, you can expect to receive approximately ₹0.37 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of INDEGENE?

INDEGENE's key financial metrics include: P/E Ratio: 35.71, P/B Ratio: 4.37, ROE: 10.19%, ROCE: 10.81%, Dividend Yield: 0.37%, EPS: ₹4.66, Book Value: ₹130.25, and Debt-to-Equity: 0. The company's market cap stands at ₹14,697.77 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is INDEGENE stock performing today in the market?

INDEGENE stock opened at ₹611.00 and is currently trading at ₹609.75, showing a decline of ₹3.60 (0.59%). The intraday high is ₹618.00 and low is ₹600.00. The trading volume stands at 2,26,254 shares, indicating moderate market participation today.

08What is the P/E ratio of INDEGENE and what does it indicate?

INDEGENE has a Price-to-Earnings (P/E) ratio of 35.71, which means investors are willing to pay 35.71 for every ₹1 of earnings. With an EPS of ₹4.66, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about INDEGENE (INDGN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.